Dominica Willmann
Overview
Explore the profile of Dominica Willmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seitz J, Auth M, Prinz T, Hau M, Tzortzoglou P, Schulz-Fincke J, et al.
Arch Pharm (Weinheim)
. 2024 Jul;
357(10):e2400450.
PMID: 39004853
Epigenetic modulators such as lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs) are drug targets for cancer, neuropsychiatric disease, or inflammation, but inhibitors of these enzymes exhibit considerable side effects....
2.
Totonji S, Ramos-Triguero A, Willmann D, Sum M, Urban S, Bauer H, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672614
Novel treatment modalities are imperative for the challenging management of muscle-invasive and metastatic BC to improve patient survival rates. The recently identified KMT9, an obligate heterodimer composed of KMT9α and...
3.
Wang S, Klein S, Urban S, Staudt M, Barthes N, Willmann D, et al.
Nat Commun
. 2024 Jan;
15(1):43.
PMID: 38167811
Inhibition of epigenetic regulators by small molecules is an attractive strategy for cancer treatment. Recently, we characterised the role of lysine methyltransferase 9 (KMT9) in prostate, lung, and colon cancer....
4.
Berlin C, Cottard F, Willmann D, Urban S, Tirier S, Marx L, et al.
Cancer Res
. 2021 Nov;
82(2):210-220.
PMID: 34737213
Colorectal cancer is among the leading causes of cancer-associated deaths worldwide. Treatment failure and tumor recurrence due to survival of therapy-resistant cancer stem/initiating cells represent major clinical issues to overcome....
5.
Herrlinger E, Hau M, Redhaber D, Greve G, Willmann D, Steimle S, et al.
Chembiochem
. 2020 Apr;
21(16):2329-2347.
PMID: 32227662
Lysine-specific demethylase 1 (LSD1) has evolved as a promising therapeutic target for cancer treatment, especially in acute myeloid leukaemia (AML). To approach the challenge of site-specific LSD1 inhibition, we developed...
6.
Haydn T, Kehr S, Willmann D, Metzger E, Schule R, Fulda S
Int J Cancer
. 2019 Nov;
146(12):3435-3449.
PMID: 31755110
Lysine-specific demethylase 1 (LSD1), a histone lysine demethylase with the main specificity for H3K4me2, has been shown to be overexpressed in rhabdomyosarcoma (RMS) tumor samples. However, its role in RMS...
7.
Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, et al.
Nat Struct Mol Biol
. 2019 May;
26(5):361-371.
PMID: 31061526
Histone lysine methylation is generally performed by SET domain methyltransferases and regulates chromatin structure and gene expression. Here, we identify human C21orf127 (HEMK2, N6AMT1, PrmC), a member of the seven-β-strand...
8.
Duteil D, Tourrette Y, Eberlin A, Willmann D, Patel D, Friedrichs N, et al.
Development
. 2018 Mar;
145(6).
PMID: 29490983
In addition to its function as an inhibitor of histone acetyltransferases, Nir (Noc2l) binds to p53 and TAp63 to regulate their activity. Here, we show that epidermis-specific ablation of Nir...
9.
Tosic M, Allen A, Willmann D, Lepper C, Kim J, Duteil D, et al.
Nat Commun
. 2018 Jan;
9(1):366.
PMID: 29371665
Satellite cells are muscle stem cells required for muscle regeneration upon damage. Of note, satellite cells are bipotent and have the capacity to differentiate not only into skeletal myocytes, but...
10.
Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kurner A, et al.
Eur J Med Chem
. 2017 Dec;
144:52-67.
PMID: 29247860
FAD-dependent lysine-specific demethylase 1 (LSD1) is overexpressed or deregulated in many cancers such as AML and prostate cancer and hence is a promising anticancer target with first inhibitors in clinical...